1. Home
  2. Primary Care
  3. Arexvy RSV Vaccine in Older Adults: Phase 3 Trial Results on Efficacy and Safety
medsynapse-hcp
4mo3 min read
Medical Article
Introduction In 2023, the FDA approved Arexvy vaccines for respiratory syncytial virus (RSV) prevention in adults aged ≥60 years (1). Initially guided by a shared clinical decision-making (SCDM) model, feedback from healthcare providers highlighted implementation challenges such as limited patient awareness about RSV risk and time constraints durin
<div>Arexvy RSV Vaccine in Older Adults: Phase 3 Trial Results on Efficacy and Safety</div>

Arexvy RSV Vaccine in Older Adults: Phase 3 Trial Results on Efficacy and Safety

Register to read more
110 Reached

Similar Content

Acute Renal Failure in Child Due to High Dose of Indomethacin
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Woman presented with Fever of Unknown Origin
Woman presented with Fever of Unknown Origin
7724 Reached93 Comments19 Likes
<p>How Physicians Should Manage Stress?</p>

How Physicians Should Manage Stress?

35294 Reached152 Comments203 Likes
Fremanezumab for Prevention and Treatment of Migraine
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Pregnant Woman with HIV-1 Infection
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes